This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics Business Update

Commercializing JETREA ® (ocriplasmin)   in the US

  • JETREA ® launched in the US on 14 January as the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA)
  • Highly focused commercial team, including specialty sales force, now working to drive the US sales of JETREA ®
  • In absence of J-code, reimbursement specialists educate physicians on ThromboGenics' comprehensive reimbursement support program to assist US physicians in gaining reimbursement for JETREA ® and explaining relevant patient assistance programs
  • Code (reimbursement code) should be in place from 1 January 2014  - J-code will automate 'bill and payment' process for practices

Positive reaction to JETREA ® from US retina community:
  • Sales of $10.2 million since the product's US launch through the end of April
  • 40% of total targeted retina practices have ordered JETREA ®
  • 50% of these practices have reordered the product

Commercializing JETREA ® in Europe and ROW
  • In March 2013, the European Medicines Agency (EMA) approved JETREA ® for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns
  • The EU approval led to ThromboGenics receiving a €45 million milestone payment from Alcon
  • Thrombogenics received a further €45 million payment from Alcon in April 2013 for the first order of JETREA ® in Europe

JETREA ® Phase IIa wet AMD trial reporting:
  • ThromboGenics today reports positive data from a Phase IIa study showing that JETREA ® has potential to resolve VMA in patients with wet age-related macular degeneration (wAMD)
  • In the study, at Day 28 (primary endpoint, p=0.26), 24% of the treated patients achieved resolution compared to 12% in the sham injection arm
  • No unexpected safety issues were identified, and the safety profile is in keeping with the previous pivotal trial data
  • To confirm these clinical results, further larger studies to confirm clinical benefits are warranted

Financial Update
  • At the end of April 2013, the Company had a cash balance exceeding €200 million
  • In March, the Company's shares started trading as part of the BEL20 index on the Euronext stock exchange.

Dr  Patrik De Haes, CEO of ThromboGenics, said: " The start of 2013 has been a very positive period for ThromboGenics with our lead product JETREA ®   being launched in the  US  and  Europe . As a result, patients and physicians on both sides of the  Atlantic  now have access to the first pharmacological treatment for symptomatic VMA/VMT, an important sight-threatening condition. We are pleased with the positive reaction to JETREA ®   from the US retina community, and are confident that this momentum will continue.

"The EU approval of JETREA ®   and its recent launch in the UK and Germany triggered a total of €90 million in milestone payments from Alcon. These funds strengthen our financial position, and will allow us to invest further in the US commercialization of JETREA ® , develop new indications for this novel medicine and expand our R&D pipeline. Over the next 12 months we expect to generate further shareholder value as the US sales of JETREA ®   continue to build and we receive royalties from Alcon as JETREA ®   continues to be rolled out across Europe."  


2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs